A Phase II Trial of DCTD-Sponsored Dasatinib (NSC #732517 IND #73969) In Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, Endometrial, or Endometriosis-Associated Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expsion.
Principal Investigator
David Hyman, MD
Status
Terminated
Date Opened To Accrual
February 03 2014
Date Closed to Accrual
August 10 2016
Date of Study Termination
June 26 2023
Disease Site
Gynecologic [GY]
Ovarian
Phase
II
Developmental Therapeutics
No
Primary Objective
To assess the clinical activity of dasatinib in patients with recurrent or persistent ovarian, fallopian tube, primary peritoneal, and endometrial clear cell carcinoma using objective tumor response (complete and partial):
- in patients without loss of BAF250a expression, and
- in patients with loss of BAF250a expression
Patient Population
Patients with recurrent or persistent ovarian, fallopian tube, primary peritoneal, and endometrial clear cell carcinoma.
Target Accrual
62
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.